In a draft policy update, NHS England is proposing to reimburse the use of tenofovir alafenamide/emtricitabine (TAF/FTC), the combination pill sold as Descovy by its manufacturers Gilead Sciences, for ‘second-line’ PrEP. This would add an additional PrEP option as currently the only combination pill reimbursable for PrEP in England is tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).
This is an unusual proposal because although TAF/FTC is approved for HIV treatment, it has not yet received authorisation for use as PrEP by the UK’s Medicine and Healthcare products Regulatory Agency (MHRA) or by the European Medicines Agency (EMA), whose decisions the MHRA usually follows.
Read the full story at Aidsmap.
Source : Aidsmap
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.